About Marie Guillou

This author has not yet filled in any details.
So far Marie Guillou has created 386 blog entries.

Webinar EB – Join the Meeting

2021-06-29T17:39:48+02:00

ERN-Skin Webinar Combined cell and gene therapy for Epidermolysis Bullosa – Michele De Luca Chaired by Cristina Has (Freiburg) / Christine Bodemer (Paris) [...]

Webinar EB – Join the Meeting2021-06-29T17:39:48+02:00

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

2024-09-26T14:24:46+02:00

J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1251-1277 S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology [...]

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)2024-09-26T14:24:46+02:00

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by EADV

2024-09-16T14:55:45+02:00

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV).

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by EADV2024-09-16T14:55:45+02:00

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study

2024-10-01T10:49:47+02:00

Publication - Epub 2020 Sep 16. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study [...]

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study2024-10-01T10:49:47+02:00

Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire

2024-10-01T10:50:35+02:00

Publication - Epub 2020 Sep 7. Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire [...]

Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire2024-10-01T10:50:35+02:00

Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research

2024-10-16T11:15:33+02:00

Publication - Epub 2020 Nov 25. Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step [...]

Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research2024-10-16T11:15:33+02:00